LCM
TENX icon

Lynx1 Capital Management’s Tenax Therapeutics TENX Stock Holding History

Lynx1 Capital Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,751
Closed -$51K – 22
2024
Q3 		$51K Buy
+14,751
New +$53.4K 0.02% 16

Other funds holding TENX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lynx1 Capital Management's TENX Position: Q4 2024 in Review

Lynx1 Capital Management sold out of Tenax Therapeutics (TENX) in Q4 2024, closing a stake of 14,751 shares — an estimated $51K sold.

Lynx1 Capital Management first reported a position in TENX in Q3 2024 and held it in 1 quarter. The position peaked at $51K in Q3 2024. 21 funds tracked by Wall St. Rank hold TENX as of Q4 2024.

  • Lynx1 Capital Management reported no remaining Tenax Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lynx1 Capital Management sold 14,751 Tenax Therapeutics shares in Q4 2024, an estimated $51K.
  • Lynx1 Capital Management first reported a position in Tenax Therapeutics in Q3 2024 and held it in 1 quarter.
  • Lynx1 Capital Management's Tenax Therapeutics position peaked at $51K in Q3 2024.
  • 21 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q4 2024.

Based on Lynx1 Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.